Business
Mesoblast holds out hope for heart failure drug – Sydney Morning Herald
Shares in the stem cell treatment developer regained some ground after a horror end to 2020.
Shares in stem cell biotech Mesoblast jumped nearly 16 per cent after the company said it would pursue approval for its key heart failure drug in the US despite a clinical trial delivering mixed results.
On Monday the company told investors that additional data from the phase 3 trial of its Revascor product showed a “substantial and durable reductions in heart attacks, strokes and cardiac deaths” in patients with chronic heart failure.
Mesoblast shares bounced after a tough end to 2020, when shares…
-
Noosa News24 hours agoLaidley e-scooter death: Tragic new details after Summah Richards killed in freak accident
-
General18 hours agoUkraine says Russia has ramped up attacks despite ‘Easter truce’
-
General21 hours agoReason v magical climate thinking – voters have no choice
-
General17 hours agoPope Francis appears Easter Sunday to deliver blessing as recovery continues